Latest news and press releases about Atossa Therapeutics, Inc. (ATOS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen.
Price
| Price | $2.42 |
| Market Cap | $24M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CGTX · CLNN · COYA · GLSI · IMMX · ONCY · SRZN
Explore sector: Healthcare · Biotechnology
More sections of ATOS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks